Tempus AI (NASDAQ:TEM) Stock Rating Lowered by William Blair

Tempus AI (NASDAQ:TEM) was downgraded by stock analysts at William Blair from an “outperform” rating to a “market perform” rating in a research report issued on Wednesday,Briefing.com Automated Import reports.

TEM has been the topic of a number of other research reports. Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and upped their target price for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Loop Capital cut their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a report on Tuesday, January 14th. Guggenheim assumed coverage on shares of Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective for the company. Bank of America increased their target price on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $56.00 price target on shares of Tempus AI in a research note on Tuesday, January 14th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Tempus AI has a consensus rating of “Moderate Buy” and an average target price of $58.55.

Tempus AI Price Performance

NASDAQ TEM opened at $71.21 on Wednesday. The company has a fifty day moving average of $44.89 and a 200 day moving average of $49.56. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI has a 1 year low of $22.89 and a 1 year high of $79.49.

Insider Transactions at Tempus AI

In other Tempus AI news, CEO Eric P. Lefkofsky sold 80,388 shares of the business’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $67.53, for a total transaction of $5,428,601.64. Following the transaction, the chief executive officer now owns 5,293,005 shares of the company’s stock, valued at approximately $357,436,627.65. The trade was a 1.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director David R. Epstein sold 620 shares of Tempus AI stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total value of $25,922.20. Following the transaction, the director now owns 27,894 shares in the company, valued at approximately $1,166,248.14. This represents a 2.17 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 2,229,449 shares of company stock valued at $102,293,124.

Institutional Trading of Tempus AI

Several hedge funds have recently made changes to their positions in TEM. Kovitz Investment Group Partners LLC purchased a new stake in Tempus AI in the 3rd quarter valued at about $1,367,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Tempus AI during the fourth quarter valued at about $1,091,000. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Tempus AI by 1,591.2% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock worth $68,922,000 after acquiring an additional 1,145,698 shares during the last quarter. Captrust Financial Advisors acquired a new position in shares of Tempus AI in the 3rd quarter worth approximately $2,726,000. Finally, Sigma Planning Corp purchased a new position in shares of Tempus AI during the 3rd quarter worth approximately $1,323,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.